HomeCompareEDRWY vs JNJ

EDRWY vs JNJ: Dividend Comparison 2026

EDRWY yields 2.69% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EDRWY wins by $50.4K in total portfolio value
10 years
EDRWY
EDRWY
● Live price
2.69%
Share price
$24.95
Annual div
$0.67
5Y div CAGR
40.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.7K
Annual income
$22,951.24
Full EDRWY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — EDRWY vs JNJ

📍 EDRWY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEDRWYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EDRWY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EDRWY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EDRWY
Annual income on $10K today (after 15% tax)
$228.26/yr
After 10yr DRIP, annual income (after tax)
$19,508.55/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, EDRWY beats the other by $15,522.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EDRWY + JNJ for your $10,000?

EDRWY: 50%JNJ: 50%
100% JNJ50/50100% EDRWY
Portfolio after 10yr
$55.5K
Annual income
$13,820.32/yr
Blended yield
24.92%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

EDRWY
No analyst data
Altman Z
1.1
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EDRWY buys
0
JNJ buys
0
No recent congressional trades found for EDRWY or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEDRWYJNJ
Forward yield2.69%2.13%
Annual dividend / share$0.67$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR40.1%28%
Portfolio after 10y$80.7K$30.3K
Annual income after 10y$22,951.24$4,689.40
Total dividends collected$54.7K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EDRWY vs JNJ ($10,000, DRIP)

YearEDRWY PortfolioEDRWY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,076$376.22$10,592$272.30+$484.00EDRWY
2$12,397$545.62$11,289$357.73+$1.1KEDRWY
3$14,065$799.60$12,123$472.89+$1.9KEDRWY
4$16,237$1,187.77$13,141$629.86+$3.1KEDRWY
5$19,169$1,795.40$14,408$846.81+$4.8KEDRWY
6$23,286$2,775.30$16,021$1,151.60+$7.3KEDRWY
7$29,330$4,414.31$18,122$1,588.22+$11.2KEDRWY
8$38,664$7,280.13$20,930$2,228.20+$17.7KEDRWY
9$53,935$12,565.48$24,792$3,191.91+$29.1KEDRWY
10$80,662$22,951.24$30,274$4,689.40+$50.4KEDRWY

EDRWY vs JNJ: Complete Analysis 2026

EDRWYStock

Electric Power Development Co., Ltd. engages in the wholesale supply of hydroelectric and thermal power in Japan. The company operates through Electric Power Business, Overseas Business, Electric Power-Related Business, and Other Business segments. It also produces wood fuel and other biomass fuels; and generates and transmits electricity. In addition, the company invests in, imports, transports, and sells coal; sells fly ash; procures forest offcut; produces and sells fertilizers; offers activated coke; operates welfare, wood pellet manufacturing, and nuclear power plants; operates and maintains telecommunication facilities and waste-fueled power generation plants; and constructs and maintains electronic and communication facilities. Further, it engages in the ocean transportation of coal for thermal power plants; research, planning, and analysis of environmental conservation; surveying and compensation for construction sites; provision of investment management, and research and development of projects; facility maintenance and business process outsourcing activities; development of computer software; and ocean transportation of ash and fly ash. Additionally, the company provides civil engineering, and construction management and services; and engineering services for atmospheric and water pollutant removal equipment. Further, it is involved in the consulting business. The company has 60 hydroelectric power plants with a total capacity of 8,560 MW; 13 thermal power generation facilities with a total capacity of 9,200 MW; 21 wind power facilities with a total capacity of 500 MW; 1 geo-thermal facility with a total capacity of 23 MW; and 2,410.1 kilometers of power transmission lines, and 9 substations and converter stations, as well as operates 33 power generation facilities with a total capacity of 6,523 MW located in Thailand, the United States, China, and internationally. The company was incorporated in 1952 and is headquartered in Tokyo, Japan.

Full EDRWY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this EDRWY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EDRWY vs SCHDEDRWY vs JEPIEDRWY vs OEDRWY vs KOEDRWY vs MAINEDRWY vs ABBVEDRWY vs MRKEDRWY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.